LSD1 inhibition: A therapeutic strategy in cancer?

James T. Lynch, William J. Harris, Tim C P Somervaille

Research output: Contribution to journalArticlepeer-review


Introduction: The role of epigenetic dysfunction in cancer is increasingly appreciated. This has raised the question as to whether enzymes that regulate the structure and function of chromatin might represent novel therapeutic targets. The histone demethylase LSD1 is one such candidate and novel, potent inhibitors are under development. Areas covered: The literature on LSD1 (also known as KDM1A, AOF2, BHC110 or KIAA0601) was identified in Pubmed and is herein discussed. Areas covered include the structure and enzymatic activity of LSD1, its role in chromatin regulatory complexes, its functional roles in normal and malignant tissue, pharmacological inhibitors of its activity and their putative therapeutic roles. Expert opinion: Pre-clinical data supporting a therapeutic role for LSD1 inhibitors are most encouraging in acute myeloid leukaemia, although optimal dosing strategies and beneficial combinations with other agents remain unclear. Studies making use of potent, selective LSD1 inhibitors active in the nanomolar range are required to establish therapeutic indications in other subtypes of haematological malignancy, and in solid tumours. © 2012 Informa UK, Ltd.
Original languageEnglish
Pages (from-to)1239-1249
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Issue number12
Publication statusPublished - Dec 2012


  • Cancer
  • Epigenetics
  • Histone demethylase
  • Leukaemia
  • LSD1
  • Tranylcypromine analogues

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'LSD1 inhibition: A therapeutic strategy in cancer?'. Together they form a unique fingerprint.

Cite this